Moderna (MRNA) Stock Surges 13% Following Strategic Investor Day Reveals

Key Takeaways

• Moderna shares climbed 13% to reach $67.50 on June 26, tracking toward the strongest close since September 2024
• The biotech firm unveiled mRNA-6007, its inaugural in vivo CAR-T initiative, focused on autoimmune conditions with clinical trials slated for 2027
• Jefferies analyst Andrew Tsai identifies late 2026 Phase III melanoma results as the critical upcoming catalyst; maintains Hold rating with $53 price target
• Edward Tenthoff of Piper Sandler boosted his target to $77 while keeping an Overweight stance
• CNBC’s Jim Cramer declared Moderna “finally investable again” while recommending investors wait for a price dip

Moderna shares experienced a 13% surge to $67.50 during the June 26 trading session, positioning the stock as the S&P 500’s top gainer that day and tracking toward its strongest closing level since September 2024. The rally followed the company’s investor day presentation, which outlined an expansive development pipeline extending far beyond its coronavirus vaccine origins.

Moderna, Inc., MRNA

The centerpiece reveal was mRNA-6007, Moderna’s inaugural in vivo CAR-T initiative. Clinical development is scheduled to commence in 2027, initially targeting B-cell-mediated autoimmune conditions such as systemic lupus erythematosus.

The in vivo CAR-T methodology engineers a patient’s T-cells to combat disease directly within the body—eliminating the need for laboratory processing. This approach offers speed and cost advantages over conventional ex vivo techniques, which require cell extraction, external modification, and reinfusion.

Moderna faces competition in this emerging field. Eli Lilly entered the space earlier this year through its planned acquisition of Orna Therapeutics to obtain its in vivo CAR-T technology. Lilly’s stock also rose 6% on June 26, driven by favorable EU regulatory feedback on Jaypirca, its oral cancer treatment.

Analyst Perspectives

Jefferies analyst Andrew Tsai characterized the early-stage oncology initiatives as having the potential to “meaningfully diversifying the mRNA pipeline.” However, he highlighted Phase III melanoma data anticipated in late 2026 as the more significant near-term catalyst for share price movement. Tsai maintains a Hold rating on Moderna, elevating his price target from $45 to $53.

Edward Tenthoff from Piper Sandler expressed greater optimism, increasing his price target from $69 to $77 while maintaining an Overweight rating. He attributed the adjustment to the pipeline advancements showcased during investor day.

On July 1, CNBC’s Jim Cramer characterized Moderna as “finally investable again,” highlighting its oncology pipeline and increasingly defined profitability trajectory. He observed that the stock has rallied nearly 150% in 2026, ranking among the S&P 500’s strongest performers this year.

Nevertheless, Cramer advocated for a measured approach. “I recommend waiting for a pullback before you buy,” he advised on Mad Money.

Development Portfolio Structure

Moderna’s investor day materials segmented its development portfolio into three strategic “horizons.” The initial tier encompasses late-stage and commercialized assets. According to Jefferies’ Tsai, the company could potentially commercialize over seven products spanning respiratory, oncology, and rare disease categories within a two-year timeframe.

This would represent substantial growth from the current three-vaccine commercial lineup. The company introduced its inaugural commercial product—the Spikevax COVID-19 vaccine—in 2020.

Current oncology initiatives include mid and late-stage clinical trials for melanoma, non-small cell lung cancer, renal cell carcinoma, and bladder cancer. A late-stage study evaluating Moderna’s Intismeran in combination with Merck’s Keytruda for secondary melanoma treatment is expected to deliver results later this year.

From a regulatory perspective, an FDA advisory panel recently recommended approval for Moderna’s investigational influenza vaccine prior to an August 5 decision deadline. The European Commission has already granted approval for the company’s combined Covid and flu vaccine.